1. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial
- Author
-
Steffen Fieuws, Bart Keymeulen, Margaretha M Visser, Christophe De Block, Chantal Mathieu, Eveline Dirinck, Liesbeth Van Huffel, Nele Myngheer, Frank Nobels, Chris Vercammen, Gerd Vanhaverbeke, Pieter Gillard, Robert Hilbrands, Sara Charleer, Toon Maes, Pathology/molecular and cellular medicine, Diabetes Clinic, and Diabetes Pathology & Therapy
- Subjects
Adult ,Blood Glucose ,Male ,Pediatrics ,medicine.medical_specialty ,type 1 diabetes ,Endocrinology, Diabetes and Metabolism ,Population ,030204 cardiovascular system & hematology ,Hypoglycemia ,Minimisation (clinical trials) ,law.invention ,03 medical and health sciences ,Insulin Infusion Systems ,0302 clinical medicine ,Belgium ,Randomized controlled trial ,Quality of life ,law ,Diabetes mellitus ,medicine ,Clinical endpoint ,Humans ,Hypoglycemic Agents ,Insulin ,Prospective Studies ,030212 general & internal medicine ,education ,Glycated Hemoglobin ,Type 1 diabetes ,education.field_of_study ,business.industry ,Blood Glucose Self-Monitoring ,ADULTS ,General Medicine ,medicine.disease ,Diabetes Mellitus, Type 1 ,Quality of Life ,Female ,Human medicine ,business - Abstract
Background People with type 1 diabetes can continuously monitor their glucose levels on demand (intermittently scanned continuous glucose monitoring [isCGM]), or in real time (real-time continuous glucose monitoring [rtCGM]). However, it is unclear whether switching from isCGM to rtCGM with alert functionality offers additional benefits. Therefore, we did a trial comparing rtCGM and isCGM in adults with type 1 diabetes (ALERTT1). Methods We did a prospective, double-arm, parallel-group, multicentre, randomised controlled trial in six hospitals in Belgium. Adults with type 1 diabetes who previously used isCGM were randomly assigned (1:1) to rtCGM (intervention) or isCGM (control). Randomisation was done centrally using minimisation dependent on study centre, age, gender, glycated haemoglobin (HbA(1c)), time in range (sensor glucose 3.9-10.0 mmol/L), insulin administration method, and hypoglycaemia awareness. Participants, investigators, and study teams were not masked to group allocation. Primary endpoint was mean between-group difference in time in range after 6 months assessed in the intention-to-treat sample. This trial is registered with ClinicalTrials.gov, NCT03772600. Findings Between Jan 29 and July 30, 2019, 269 participants were recruited, of whom 254 were randomly assigned to rtCGM (n=127) or isCGM (n=127); 124 and 122 participants completed the study, respectively. After 6 months, time in range was higher with rtCGM than with isCGM (59.6% vs 51.9%; mean difference 6.85 percentage points [95% CI 4.36-9.34]; p
- Published
- 2021
- Full Text
- View/download PDF